trustme.bro/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Serotonin antagonists and reuptake inhibitors treat depression by increasing synaptic serotonin

the verdict
SUPPORTED
the evidence backs this
Recorded sources
4 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Clinical and neuroimaging studies consistently demonstrate that serotonin reuptake inhibitors and related antidepressant medications achieve their therapeutic effects in part by binding to and blocking serotonin transporters, thereby increasing synaptic serotonin levels.

The analysis

Papers [0], [1], [2], and [5] directly support the premise that serotonin reuptake inhibitors act by targeting the serotonin transporter and increasing synaptic availability, aligning with standard pharmacological mechanisms of these antidepressants.

Evidence for · 4
Serotonin transporter occupancy with TCAs and SSRIs: a PET study in patients with major depressive disorder
Recorded source metadata

J. Lundberg, M. Tiger, M. Landén, C. Halldin, L. Farde. Serotonin transporter occupancy with TCAs and SSRIs: a PET study in patients with major depressive disorder. 2012. https://doi.org/10.1017/S1461145711001945

Demonstrates that TCAs and SSRIs share a mechanism of action via serotonin transporter inhibition.

See more details
More for · 3
Serotonin Transporter Occupancy and the Functional Neuroanatomic Effects of Citalopram in Geriatric Depression
Recorded source metadata

Gwenn S. Smith, Alan Kahn, J. Sacher, P. Rusjan, Thilo van Eimeren, A. Flint, Alan A. Wilson. Serotonin Transporter Occupancy and the Functional Neuroanatomic Effects of Citalopram in Geriatric Depression. 2011. https://doi.org/10.1097/JGP.0b013e318227f83f

Shows that SSRI treatment results in significant serotonin transporter occupancy in human brain regions.

Molecular Imaging of the Serotonin Transporter Availability and Occupancy by Antidepressant Treatment in Late-Life Depression
Recorded source metadata

Gwenn S. Smith, H. Kuwabara, Neda F. Gould, Najilla Nassery, A. Savonenko, J. Joo, K. Bigos, M. Kraut, James Robert Brašić, D. Holt, Andrew W. Hall, W. B. Mathews, R. Dannals, A. Nandi, C. Workman. Molecular Imaging of the Serotonin Transporter Availability and Occupancy by Antidepressant Treatment in Late-Life Depression. 2021. https://doi.org/10.1016/j.neuropharm.2021.108447

Finds that antidepressant treatment leads to high serotonin transporter occupancy which correlates with clinical improvement.

Neural signaling mechanisms in depression: bridging classical monoamine hypotheses, animal models, and emerging antidepressant strategies.
Recorded source metadata

Yamamoto M, Hirakata H, Toda K. Neural signaling mechanisms in depression: bridging classical monoamine hypotheses, animal models, and emerging antidepressant strategies.. 2026. https://doi.org/10.3389/fcell.2026.1777975

Confirms that widely prescribed antidepressants like SSRIs and SNRIs were developed based on monoaminergic neurotransmission hypotheses.

The paper trail · every fact has a biography
first checked01 Aug 2026
judged → SUPPORTED · 8601 Aug 2026
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.
trust me, bro: win the argument, pass the class, survive peer review.

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work · Dispute this receipt